- Home
- BKD vs AUPH Comparison
BKD vs AUPH Comparison
Compare BKD & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKD
- AUPH
- Stock Information
- Founded
- BKD 2005
- AUPH 1993
- Country
- BKD United States
- AUPH Canada
- Employees
- BKD 36000
- AUPH N/A
- Industry
- BKD Hospital/Nursing Management
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- BKD Health Care
- AUPH Health Care
- Exchange
- BKD Nasdaq
- AUPH Nasdaq
- Market Cap
- BKD 1.5B
- AUPH 999.8M
- IPO Year
- BKD 2005
- AUPH 1999
- Fundamental
- Price
- BKD $6.65
- AUPH $8.11
- Analyst Decision
- BKD Buy
- AUPH Strong Buy
- Analyst Count
- BKD 5
- AUPH 2
- Target Price
- BKD $7.70
- AUPH $11.50
- AVG Volume (30 Days)
- BKD 3.3M
- AUPH 966.4K
- Earning Date
- BKD 05-06-2025
- AUPH 05-12-2025
- Dividend Yield
- BKD N/A
- AUPH N/A
- EPS Growth
- BKD N/A
- AUPH N/A
- EPS
- BKD N/A
- AUPH 0.04
- Revenue
- BKD $3,015,786,000.00
- AUPH $235,133,000.00
- Revenue This Year
- BKD $8.73
- AUPH $11.86
- Revenue Next Year
- BKD N/A
- AUPH $24.96
- P/E Ratio
- BKD N/A
- AUPH $203.75
- Revenue Growth
- BKD 4.05
- AUPH 33.97
- 52 Week Low
- BKD $4.45
- AUPH $4.98
- 52 Week High
- BKD $8.12
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- BKD 61.51
- AUPH 52.49
- Support Level
- BKD $6.07
- AUPH $7.92
- Resistance Level
- BKD $6.80
- AUPH $8.38
- Average True Range (ATR)
- BKD 0.26
- AUPH 0.23
- MACD
- BKD 0.03
- AUPH 0.03
- Stochastic Oscillator
- BKD 83.09
- AUPH 63.01
About BKD Brookdale Senior Living Inc.
Brookdale Senior Living Inc operates senior living communities throughout the United States. The company has three reportable segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRs). The majority of the revenue is generated from the Assisted Living and Memory Care segment, which offers housing and assistance with activities of daily living to its customers. The company generates revenue in the form of Resident Fees, which it receives in exchange for the services provided, and in the form of management fees from certain communities under contract in exchange for the management services provided.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.